Skip to main content
. 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786

Figure 3.

Figure 3

Anti-SARS-CoV-2 IgG titers (A) and IFN-γ levels (B) in the early and late samples of patients classified according to their DMTs. (A) Dotted line marks anti-spike IgG antibody titers considered protective (260 BAU/mL). (B) Dotted line marks IFN-γ levels of 80 pg/mL that were considered positive. ACD20: anti-CD20 therapies; ALE: alemtuzumab CLAD: cladribine; E: early sample; FIN: fingolimod; FLT: first-line therapies; L: late sample; NAT: natalizumab; NTP: non-treated patients.